ENGLEWOOD, Colo., Nov. 29,
2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE
American: AMPE), a biopharmaceutical company focused on the
advancement of immunology-based therapies for prevalent
inflammatory conditions, today announced it will host a business
update call with its chairman and CEO, Mike
Martino, at 4:30 p.m. EST on
Wednesday, Dec. 1, 2021. Investors and analysts can access
via the information provided below:
Webcast Link:
https://event.on24.com/wcc/r/3543501/784479B739F2EB467C477016E7FAD06A
|
Conference Call
(listen only)
|
|
|
Canada dial-in number
(Toll Free):
|
1 833 950
0062
|
|
Canada dial-in number
(Local):
|
1 226 828
7575
|
|
United States:
|
1 844 200
6205
|
|
United States
(Local):
|
1 646 904
5544
|
|
All other locations:
|
1 929 526
1599
|
|
Access
code:
|
948260
|
|
*Participants will
need to enter the participant access code before being met by an
operator
|
In order to submit questions, participants must have Internet
connectivity, as questions will only be addressed via the
webcast. The conference call line will be in listen-only
mode.
The conference call and webcast can also be accessed from the
Investor Relations section of the Company's website at
www.ampiopharma.com and will be archived there shortly after the
live event.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company
primarily focused on the advancement of immunology-based therapies
to treat prevalent inflammatory conditions for which there are
limited treatment options. Ampio's lead drug, Ampion™, is backed by
an extensive patent portfolio with intellectual property protection
extending through 2037 and may be eligible for 12-year FDA market
exclusivity upon approval as a novel biologic under the Biologics
Price Competition and Innovation Act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion and its classification, as
well as those associated with regulatory approvals and other FDA
decisions, the Biological License Application (BLA), the ability of
Ampio to enter into partnering arrangements,
clinical trials and decisions and changes in business
conditions and similar events, the ability to receive regulatory
approval to conduct clinical trials, that Ampion may be used to
treat ARDS induced by COVID-19, all of which are inherently subject
to various risks and uncertainties. The risks and uncertainties
involved include those detailed from time to time in Ampio's
filings with the Securities and Exchange Commission, including
without limitation, under Ampio's Annual Report on Form 10-K and
other documents filed with the Securities and Exchange Commission.
Ampio undertakes no obligation to revise or update these
forward-looking statements, whether as a result of new information,
future events or otherwise.
Investor and Media Contacts:
Tony Russo or Nic Johnson
Russo Partners
info@ampiopharma.com
tony.russo@russopartnersllc.com
nic.johnson@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-to-host-business-update-call-with-chairman-and-ceo-mike-martino-on-wednesday-dec-1-301433202.html
SOURCE Ampio Pharmaceuticals, Inc.